What's driving the surge in UK private health insurance?
In recent years, a trend has emerged across the UK where nearly one in eight Britons now have private medical insurance. Yahoo Finance UK spoke to LifeSearch CEO Debbie Kennedy to shed light on what is driving this growing reliance on private healthcare.
With NHS waiting lists stretching into months and families increasingly anxious about timely access to medical services, Kennedy explains that many are turning to private insurance not just as a safety net for hospital treatment, but as a proactive way to ensure quicker access to primary care, diagnostics and even mental health services.
Kennedy highlighted some striking figures during the interview. According to industry data from 2023, approximately 4.7 million people in the UK had private medical insurance, with more than 400,000 new policies taken out in that year alone.
'There has been a surge,' Kennedy noted. 'We are all acutely aware of the strain on the NHS – not just the 18-month waiting lists for operations, but the everyday challenges of getting GP appointments and prompt diagnoses.'
Read more: How to achieve financial stability in retirement
For many, the decision to secure private cover is about more than just emergency treatments. It's about ensuring that when a health concern arises — whether it be a persistent ailment, a sudden injury or even mental health issues – there is a faster, more accessible route to care.
As Kennedy explained, the issue isn't solely about what happens if one is admitted to hospital. 'It's more about, how do I get to see someone to talk about a concern I have? How do I get a diagnosis?'
This sentiment has resonated with a growing number of individuals who see private insurance as a means to bypass some of the bureaucratic delays in the public healthcare system.
With the NHS facing ever-increasing demand, the appeal of being able to consult a GP quickly, access early screening tests, or receive specialist care without long waiting times has never been higher.
Kennedy noted that private insurers are evolving to meet modern healthcare needs. 'Insurers are now developing better products,' she explained.
'It's not just about gold-plated employee schemes anymore. There are products with everyday benefits that cater to a range of needs – from physiotherapy and fracture cover to mental health support, including talking therapy sessions.'
Read more: UK buy-to-let investors look North in search of higher yields
This evolution in product offerings means that private medical insurance is becoming accessible to a broader spectrum of the population. Consumers today can choose policies that fit their budget without sacrificing essential benefits.
Kennedy stressed the importance of shopping around and doing thorough research. 'It is important to shop around, do the research and yes, do ask an adviser if you want help on this,' she advised.
Despite the growing popularity of private medical insurance, many consumers still harbour concerns about claims and payouts. Kennedy acknowledged these fears, noting that it is a common worry among potential policyholders. 'I even have family and friends say the same to me, 'Oh, but I bet you won't ever pay out," she added.
Read more: Mortgage mistakes to avoid for first-time buyers and wealthy individuals
To address this scepticism, Kennedy pointed to claims statistics that reveal over 98% of claims are paid out – a figure that underscores the reliability of these products.
'When you look at the claim statistics for our industry and life insurance protection, it's clear that we do pay out,' Kennedy said. She added that this data comes from figures provided by the Association of British Insurers, which has mandated transparency across the board.
At the end of the day, you might have your policy for 10 to 15 years before you need to use it,' Kennedy explained. 'It is essential that you have confidence that it will work.'
In today's digital age, Kennedy said that efficiency and ease of access are paramount. While many industries are being transformed by technology, the life insurance sector has been somewhat slow to embrace these changes. Kennedy, however, sees a bright future where technology and human service are seamlessly integrated.
'Customers want to do things online, and they want to do it easily,' she observed. Yet the digital experience isn't simply about digitising paper forms – it's about creating smarter, more intuitive journeys that guide customers through the often complex process of taking out a policy. Kennedy envisions a future where digital platforms not only facilitate transactions but also provide timely human support.
'If someone needs reassurance or advice during the application process, they should be able to speak to a real advisor,' she emphasised.
Often, discussions about insurance tend to focus on older demographics, under the assumption that younger individuals are at lower risk. Kennedy, however, challenges this notion, arguing that even those in their 20s and 30s stand to benefit significantly from taking out insurance policies early.
'Many young people think, 'My risk of dying is probably low,' but in your 30s, you're actually eight times more likely to have an accident and be off work for at least two months than to die,' she explained.
The financial implications of a prolonged absence from work can be severe – ranging from loss of income to difficulties in managing everyday expenses. This is where income protection or sick pay cover becomes critically important.
Moreover, younger policyholders often benefit from lower premiums since rates are largely age-dependent and many will be in good health when they first take out a policy. Kennedy also highlighted the flexibility of modern policies that can adapt as one's life circumstances change. Whether it's securing a mortgage, starting a family or changing jobs, the benefits embedded in these policies can be adjusted without the need to reapply.
'It's about looking beyond the death benefit,' she explained. 'There's a suite of benefits that make these policies relevant to a younger audience.'
Read more: How will Trump's tariffs impact UK and EU trade?
For those contemplating private medical insurance, Kennedy offers some prudent advice.
First and foremost, consumers should conduct thorough research and compare products across different insurers. 'It is important to shop around and ask for advice,' she stressed. The variety in products means that there is likely a policy that can be tailored to individual needs and budgets.
Additionally, transparency in claims processing is crucial. By understanding the performance of the industry – backed by figures from the Association of British Insurers – consumers can gain further insight about whether insurers will honour claims when it matters most.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Weight loss pill set to rival injections after promising studies
A new daily weight loss pill has shown promising results in initial studies. Researchers say amycretin, which can be offered by injection or tablet, helped patients lose a significant amount of weight in the first trials. Those who received higher doses of amycretin as a weekly jab lost 24.3 per cent of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks. While weight loss jabs have been hailed as transformative by NHS leaders, injections come with additional work for over-stretched health services, so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs of improving blood sugar levels. Side effects included nausea and vomiting, and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.
Yahoo
6 hours ago
- Yahoo
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
The Hill
7 hours ago
- The Hill
Vaccine advisers set to review ingredient in influenza shot
PRESENTED BY The Big Story Coming next week: The first meeting of RFK Jr.'s handpicked vaccine advisory panel. © Photo credit It's the first meeting of the Advisory Committee on Immunization Practices (ACIP) since Kennedy fired all 17 members and appointed eight new panelists, several of whom are vocal vaccine critics. As part of its scaled-down two-day meeting beginning Wednesday, the committee is set to vote on influenza vaccines that contain thimerosal — an ingredient wrongly linked to autism. Kennedy has long advocated for banning thimerosal, a preservative that was widely used for decades in a number of biological and drug products, including many vaccines. In his 2014 book, Kennedy said thimerosal was 'toxic to brain tissue' and likely caused autism. Thimerosal, a compound that contains mercury, is used as a preservative to prevent harmful bacteria in multidose vials of vaccines. The compound has been largely phased out as manufacturers have shifted toward single-use vials that contain little or no thimerosal, according to the Centers for Disease Control and Prevention (CDC). Thimerosal was largely removed from pediatric vaccines by 2001, amid concerns that it could be linked to autism in children. But according to the CDC, 'a robust body of peer-reviewed scientific studies conducted in the U.S. and other countries support the safety of thimerosal-containing vaccines.' The draft agenda for next week's ACIP meeting revisits issues that scientists and public health experts have long considered to be settled, including the use of the measles mumps, rubella and varicella vaccine in children under 5 years old. It's unclear yet what the panel will discuss regarding the shot. The current CDC childhood vaccine schedule recommends two doses for children, with the first dose at age 12-15 months and the second at age 4-6 years. CDC suggests that the MMR vaccine be given rather than MMRV for the first dose, but both shots have been on the schedule for decades. Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel, Joseph Choi and Alejandra O'Connell-Domenech — every week we follow the latest moves on how Washington impacts your health. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the health care sector this week and beyond: Trump administration makes sweeping changes to ObamaCare, ends 'Dreamer' coverage The Trump administration is shortening ObamaCare's annual open enrollment period and ending the law's coverage of immigrants that entered the U.S. illegally as children, according to a final rule announced Friday. The Biden administration made it easier and more affordable to sign up for Affordable Care Act plans, causing enrollment to swell to an all-time high. The Trump administration claims those moves opened a wave … New COVID-19 variant causes 'razor blade throat' Patients and doctors say the latest COVID-19 variant spreading in the U.S. in some cases causes a sore throat so painful it has earned the nickname 'razor blade throat.' The nimbus variant, which is officially known as NB.1.8.1., is a descendant of the omicron and is being monitored by the World Health Organization. 'Your throat is so dry, so cracked, it's so painful, it's even hard to drink sometimes,' Muhammad Azam, … ChatGPT use linked to cognitive decline: MIT research ChatGPT can harm an individual's critical thinking over time, a study released this month suggests. Researchers at MIT's Media Lab asked subjects to write several SAT essays and separated subjects into three groups — using OpenAI's ChatGPT, using Google's search engine and using nothing, which they called the 'brain‑only' group. Each subject's brain was monitored through electroencephalography (EEG), … On Our Radar Upcoming news themes and events we're watching: In Other News Branch out with a different read from The Hill: Agencies they can't enforce anti-trans bias policies against Catholic groups: Judge BISMARCK, N.D. (AP) — Two federal agencies cannot punish Catholic employers and health care providers if they refuse for religious reasons to provide gender-affirming care to transgender patients or won't provide health insurance coverage for such care to their workers, a federal judge ruled Thursday. The ruling from U.S. District … A MESSAGE FROM ALLIANCE FOR AGING RESEARCH Around the Nation Local and state headlines on health care: What We're Reading Health news we've flagged from other outlets: What Others are Reading Most read stories on The Hill right now: Senate parliamentarian knocks pieces out of Trump's megabill Senate Parliamentarian Elizabeth MacDonough has ruled that several key pieces of the massive bill to implement President Trump's agenda run afoul of … Read more Supreme Court rules against FDA, EPA 12:30 Report is The Hill's midday newsletter. Subscribe here or using the box below: Close Thank you for signing up! Subscribe to more newsletters … Read more What People Think Opinions related to health submitted to The Hill: You're all caught up. See you next week! Thank you for signing up! Subscribe to more newsletters here
